

# Steven Goossens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5121316/publications.pdf>

Version: 2024-02-01

56  
papers

2,408  
citations

279798

23  
h-index

214800

47  
g-index

57  
all docs

57  
docs citations

57  
times ranked

5057  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy. <i>Cancers</i> , 2022, 14, 902.	3.7	39
2	Myb drives B-cell neoplasms and myeloid malignancies in vivo. <i>Blood Advances</i> , 2022, 6, 2987-2991.	5.2	1
3	MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus. <i>JCI Insight</i> , 2022, 7, .	5.0	7
4	Distinct Transcriptional Programs in Ascitic and Solid Cancer Cells Induce Different Responses to Chemotherapy in High-Grade Serous Ovarian Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1532-1547.	3.4	2
5	RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. <i>Science Advances</i> , 2022, 8, .	10.3	15
6	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
7	The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL. <i>Blood Advances</i> , 2021, 5, 1963-1976.	5.2	9
8	Pancreas morphogenesis and homeostasis depends on tightly regulated Zeb1 levels in epithelial cells. <i>Cell Death Discovery</i> , 2021, 7, 138.	4.7	3
9	Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	12
10	Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity. <i>PLoS Biology</i> , 2021, 19, e3001394.	5.6	18
11	Unlike its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival. <i>Cells</i> , 2021, 10, 192.	4.1	5
12	Direct and indirect anti-leukemic properties of Activity-on-Target interferons for the treatment of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, , .	3.5	2
13	Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. <i>Blood</i> , 2020, 135, 1685-1695.	1.4	28
14	The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1. <i>Blood</i> , 2020, 136, 957-973.	1.4	35
15	Zeb2 drives invasive and microbiota-dependent colon carcinoma. <i>Nature Cancer</i> , 2020, 1, 620-634.	13.2	29
16	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. <i>Cancer Research</i> , 2020, 80, 2983-2995.	0.9	51
17	Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2020, 1, 274-289.	5.0	21
18	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. <i>Haematologica</i> , 2019, 104, e17-e20.	3.5	18

#	ARTICLE	IF	CITATIONS
19	Genetic characterization and therapeutic targeting of <i>MYC</i> -rearranged T cell acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 185, 169-174.	2.5	9
20	Targeting steroid resistance in T-cell acute lymphoblastic leukemia. Blood Reviews, 2019, 38, 100591.	5.7	20
21	Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies. Scientific Reports, 2019, 9, 10577.	3.3	5
22	ZEB2 in T-cells and T-ALL. Advances in Biological Regulation, 2019, 74, 100639.	2.3	7
23	ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms. Haematologica, 2019, 104, 1608-1616.	3.5	22
24	USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia. Clinical Cancer Research, 2019, 25, 222-239.	7.0	66
25	LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. Blood, 2018, 131, blood-2017-05-786962.	1.4	32
26	A Novel <i>Asparaginase</i> with low <i>Glutaminase</i> Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias <i>In Vivo</i> . Cancer Research, 2018, 78, 1549-1560.	0.9	67
27	A knock-in/knock-out mouse model of HSPB8-associated distal hereditary motor neuropathy and myopathy reveals toxic gain-of-function of mutant Hspb8. Acta Neuropathologica, 2018, 135, 131-148.	7.7	58
28	ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?. HemaSphere, 2018, 2, e43.	2.7	23
29	ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transition. Epigenetics and Chromatin, 2018, 11, 70.	3.9	15
30	Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice. Scientific Reports, 2018, 8, 7642.	3.3	10
31	Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia. Blood, 2017, 129, 981-990.	1.4	17
32	Novel oncogenic noncoding mutations in T-ALL. Blood, 2017, 129, 3140-3142.	1.4	5
33	Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity. Trends in Genetics, 2017, 33, 943-959.	6.7	205
34	Structure-function Studies in Mouse Embryonic Stem Cells Using Recombinase-mediated Cassette Exchange. Journal of Visualized Experiments, 2017, , .	0.3	4
35	EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 584-591.	7.4	214
36	Zeb2 Regulates Cell Fate at the Exit from Epiblast State in Mouse Embryonic Stem Cells. Stem Cells, 2017, 35, 611-625.	3.2	41

#	ARTICLE	IF	CITATIONS
37	p120 Catenin-Mediated Stabilization of E-Cadherin Is Essential for Primitive Endoderm Specification. PLoS Genetics, 2016, 12, e1006243.	3.5	26
38	Characterization of New Transgenic Mouse Models for Two Charcot-Marie-Tooth-Causing HspB1 Mutations using the Rosa26 Locus. Journal of Neuromuscular Diseases, 2016, 3, 183-200.	2.6	9
39	LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19. Haematologica, 2016, 101, e240-e244.	3.5	18
40	Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia. PLoS Medicine, 2016, 13, e1002208.	8.4	16
41	Strategies to Rescue the Consequences of Inducible Arginase-1 Deficiency in Mice. PLoS ONE, 2015, 10, e0125967.	2.5	12
42	ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nature Communications, 2015, 6, 5794.	12.8	75
43	Novel biological insights in T-cell acute lymphoblastic leukemia. Experimental Hematology, 2015, 43, 625-639.	0.4	97
44	Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. Journal of Experimental Medicine, 2015, 212, 2015-2025.	8.5	151
45	Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. Journal of Experimental Medicine, 2015, 212, 2027-2039.	8.5	206
46	Alpha-Catenins Control Cardiomyocyte Proliferation by Regulating Yap Activity. Circulation Research, 2015, 116, 70-79.	4.5	106
47	Controlling Pre-leukemic Thymocyte Self-Renewal. PLoS Genetics, 2014, 10, e1004881.	3.5	8
48	MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia. Haematologica, 2014, 99, 1326-1333.	3.5	55
49	Loss of autocrine endothelial-derived VEGF significantly reduces hemangiosarcoma development in conditional p53-deficient mice. Cell Cycle, 2014, 13, 1501-1507.	2.6	10
50	ZEB2-transgene expression in the epidermis compromises the integrity of the epidermal barrier through the repression of different tight junction proteins. Cellular and Molecular Life Sciences, 2014, 71, 3599-609.	5.4	20
51	ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood, 2014, 124, 3738-3747.	1.4	198
52	Efficient ROSA26-Based Conditional and/or Inducible Transgenesis Using RMCE-Compatible F1 Hybrid Mouse Embryonic Stem Cells. Stem Cell Reviews and Reports, 2013, 9, 774-785.	5.6	37
53	The ROSA26-iPSC Mouse: A Conditional, Inducible, and Exchangeable Resource for Studying Cellular (De)Differentiation. Cell Reports, 2013, 3, 335-341.	6.4	35
54	Zeb2-Deficiency in the Adult Murine Hematopoietic Precursor Cells Leads to Differentiation Defects in Multiple Hematopoietic Lineages and a Myeloproliferative-Like Phenotype. Blood, 2012, 120, 1199-1199.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The EMT regulator Zeb2/Sip1 is essential for murine embryonic hematopoietic stem/progenitor cell differentiation and mobilization. Blood, 2011, 117, 5620-5630.	1.4	94
56	Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells. Nucleic Acids Research, 2009, 37, e55-e55.	14.5	99